• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Vedanta Biosciences

    Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at Upcoming Investor Conferences
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Participate at Upcoming Investor Conferences
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at Upcoming Investor Conferences
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at Upcoming Investor Conferences
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
    From Vedanta Biosciences
    Via Business Wire
    Tickers PRTC
    Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
    From Vedanta Biosciences
    Via Business Wire
    Tickers PRTC
    Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
    From Vedanta Biosciences
    Via Business Wire
    Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
    From Vedanta Biosciences
    Via Business Wire
    Tickers PRTC
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.